Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today ...
Acoramidis-mediated Improvement in NT-proBNP at Month 30 Compared with Placebo in Patients with ATTR-CM: Results from the ATTRibute-CM StudyPresenter: Nitasha Sarswat, M.D. of UChicago Medicine, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback